HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-18-2014, 02:06 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu

Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer.



Abstract No:
615
Attend this session at the
2014 ASCO Annual Meeting!


Session: Breast Cancer - HER2/ER
Type: General Poster Session
Time: Monday June 2, 8:00 AM to 11:45 AM
Location: S Hall A2
Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Mary L. Disis, Andrew L Coveler, Doreen Higgins, Leonard A D'Amico, Chihiro Morishima, James Ross Waisman, Jessica Reichow, Jennifer Childs, Yushe Dang, Lupe G. Salazar, Edmond Marzbani; University of Washington, Seattle, WA; City of Hope, Duarte, CA
Abstract Disclosures

Abstract:

Background: We have reported that infusion of ex vivo expanded T cells derived from previously HER2-vaccine-primed PBMC is safe and able to mediate an anti-tumor response in patients with HER2+ breast cancer (Disis 2013). In this study, we evaluated the safety and clinical efficacy of infusion of HER2 specific T cells after rapid HER2 vaccinations in patients with advanced stage HER2+ breast cancer. Methods: 19patients were vaccinated three times weekly with a HER2 peptide based vaccine. HER2 specific T-cells were expanded 2 weeks after 3rd vaccine. The patients received 2-3 escalating doses of T-cells given at 7-10 day intervals. Cyclophosphamide was administrated before the first dose of T- cells. One patient underwent indium-111 labeling of T-cells for SPECT/CT scanning. Results: All patients received at least two doses of HER2 specific expanded T-cells. The infused T-cell products were >98% of CD3+ with an average of 43% CD4+ and 54% CD8+ T-cells. The total number of T-cells infused was 0.3x109 – 57.1x109 (median 17.5x109). Subjects tolerated the infusions well with 95% of adverse events of grade 1 or 2. There were no complete or partial responses. 59% had stable disease (SD) 1-3 months after infusion and 41% of the patients demonstrated progressive disease (PD). The frequencies of HER2 specific T-cells in the infused products were significantly higher in patients with SD than that in PD (p=0.039). The percentage of CD4+ cells in products was positively correlated with HER2 specific T-cells (p=0.017). HER2 immunity was generated in vivo and augmented in magnitude after infusion and was maintained 3-9 months post infusion in the majority of patients. SPECT/CT of In-111 labeled T-cells demonstrated cell trafficking to all sites of metastatic disease. Conclusions: Adoptive transfer of HER2 specific T-cells generated from PBMC after rapid immunization is feasible and safe. Clinical outcome is associated with the frequency of HER2 specific CD4 T-cells present in the infusion product. Clinical trial information: NCT00791037.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:49 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter